Stockscreener 앱 받기
32.28
0.03%
0.08
전일 마감가:
$32.20
열려 있는:
$31.92
하루 거래량:
363.21K
Relative Volume:
0.25
시가총액:
$3.76B
수익:
$10.12M
순이익/손실:
$-280.49M
주가수익비율:
-11.17
EPS:
-2.89
순현금흐름:
$-188.51M
1주 성능:
+3.22%
1개월 성능:
+21.22%
6개월 성능:
-28.57%
1년 성능:
+21.77%
1일 변동 폭
$31.45
$32.70
1주일 범위
$30.66
$33.62
52주 변동 폭
$21.51
$56.00
어비디티 바이오사이언스 Stock (RNA) Company Profile
명칭
Avidity Biosciences Inc
전화
858-401-7900
주소
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
RNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
32.27 | 3.76B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.73 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.64 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.50 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.84 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
어비디티 바이오사이언스 Stock (RNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-20 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-09-24 | 개시 | Goldman | Buy |
| 2024-08-28 | 개시 | Barclays | Overweight |
| 2024-05-03 | 개시 | BofA Securities | Buy |
| 2024-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-05-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-31 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Strong Buy |
| 2021-09-07 | 개시 | Evercore ISI | Outperform |
| 2021-06-17 | 개시 | Needham | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | Cowen | Outperform |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | SVB Leerink | Outperform |
| 2020-07-07 | 개시 | Wells Fargo | Overweight |
모두보기
어비디티 바이오사이언스 주식(RNA)의 최신 뉴스
Avidity Biosciences chief program officer sells $190k in stock By Investing.com - Investing.com Nigeria
Avidity Biosciences chief program officer sells $190k in stock - Investing.com
Avidity Biosciences appoints Deloitte as new auditor By Investing.com - Investing.com Canada
Avidity Biosciences appoints Deloitte as new auditor - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Avidity Biosciences' RNA Drug for DM1 Gains Orphan Status in Jap - GuruFocus
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 (PR Newswire) - Aktiellt
Avidity’s del-desiran for DM1 named orphan drug in Japan - Muscular Dystrophy News
Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock - Benzinga
Japan grants Avidity’s DM1 drug Orphan status By Investing.com - Investing.com South Africa
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - StreetInsider
Avidity Biosciences Receives Orphan Drug Designation in Japan fo - GuruFocus
Avidity Says Japan Grants Orphan Drug Status to Del-Desiran for Myotonic Dystrophy Type 1 - marketscreener.com
Japan grants Avidity's DM1 drug Orphan status By Investing.com - Investing.com India
Japan grants Avidity's DM1 drug Orphan status - Investing.com
Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran - MarketScreener
Myotonic Dystrophy Pipeline Analysis and Clinical Trials - openPR.com
Avidity Biosciences chief program officer sells shares worth $206,799 - MSN
Avidity Biosciences CFO sells $93,985 in stock - MSN
Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money - MSN
Avidity Biosciences’ chief program officer sells $163k in stock - Investing.com India
Avidity Biosciences’ chief program officer sells $163k in stock By Investing.com - Investing.com UK
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? - Nasdaq
When the Price of (RNA) Talks, People Listen - news.stocktradersdaily.com
Avidity Biosciences : to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020 - marketscreener.com
Avidity Biosciences to Participate in Upcoming Investor Conference - StreetInsider
Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress - Investing.com India
Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock - Investing.com Australia
Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock By Investing.com - Investing.com Canada
Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress By Investing.com - Investing.com South Africa
Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy - MarketScreener
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy - StreetInsider
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy – Company AnnouncementFT.com - Financial Times
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
EFG Asset Management North America Corp. Purchases 58,198 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (NASDAQ:RNA) - Seeking Alpha
Avidity Biosciences chief scientific officer sells $365,867 in stock By Investing.com - Investing.com Australia
Avidity Biosciences CFO Michael MacLean sells $246,424 in stock By Investing.com - Investing.com Australia
Avidity Biosciences Inc Stock: Leadership Sells Shares Amid Clinical Success - Sharewise
Avidity Biosciences chief HR officer sells $241,583 in stock By Investing.com - Investing.com Australia
Avidity Biosciences chief HR officer sells $241,583 in stock - Investing.com India
Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock - Investing.com India
Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences chief scientific officer sells $365,867 in stock - Investing.com
Avidity Biosciences chief medical officer sells $297,490 in stock - Investing.com
Avidity Biosciences Executives Sell Shares for Tax Obligations - TradingView
어비디티 바이오사이언스 (RNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
어비디티 바이오사이언스 주식 (RNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gallagher Kathleen P. | Chief Program Officer |
May 01 '25 |
Sale |
32.40 |
5,875 |
190,324 |
50,554 |
0.27%
0.30%
자본화:
|
볼륨(24시간):